Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

21 Feb 2024

Abstract excerpt

Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients but has been difficult to capture in laboratory models. Here, we present a preclinical system that recapitulates acquired cross-resistance, developed from 51 patient-derived xenograft (PDX) models. Each model was tested in vivo against three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38386926
DOI: 10.1158/2159-8290.cd-23-0656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC ParalogsPMID 38386926Read ↗

Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of <i>MYC</i> paralogsSemantic proximity Read ↗

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancerSemantic proximity Read ↗

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancerSemantic proximity Read ↗

Evolutionary trajectories of small cell lung cancer under therapy.Semantic proximity Read ↗

Genomic evolution of non-small cell lung cancer patient-derived xenograft modelsSemantic proximity Read ↗

Clinically relevant shifts in endogenous and exogenous mutational processes proximate to metastasis support local consolidative treatment in EGFR-driven non-small cell lung cancerSemantic proximity Read ↗

Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responsesSemantic proximity Read ↗

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancerSemantic proximity Read ↗

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsSemantic proximity Read ↗

SBRT for oligoprogressive oncogene addicted NSCLC.Semantic proximity Read ↗

Integrative Genomic Analysis of Drug Resistance in MET Exon 14 Skipping Lung Cancer Using Patient-Derived Xenograft ModelsSemantic proximity Read ↗

Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.